BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018.
BIOLIFE4D’s modified Regulation A+ offering will allow the company to sell up to 3,965,493 shares of its securities to the public. BIOLIFE4D is now offering shares at $13.50 USD per share with a minimum investment of 80 shares for $1,080 USD. The offering will be conducted on a best efforts basis through our website, https://biolife4d.com/investing-in-biolife/, where a link to the Offering Circular relating to the offering is posted.
BIOLIFE4D has chosen to raise its share price after reaching a significant scientific milestone of 3D bioprinting a mini-heart, which has been featured in high profile publications like Forbes, Digital Trends Live, NBC Chicago, Engadget, and more. BIOLIFE4D believes it is advancing rapidly, and is well ahead of schedule in its scientific process as it seeks to 3D bioprint a viable human heart for transplant.
To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.
About BIOLIFE4D
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally.